跳转至内容
Merck
CN
所有图片(2)

文件

安全信息

HCMP1MAG-19K

Millipore

MILLIPLEX® 人补体板1 - 免疫学多重检测

The Human Complement Panel 1 Bead-Based Multiplex Assay kit, using the Luminex xMAP technology, enables the simultaneous analysis of complement proteins and factors in human serum, plasma and cell culture samples.

别名:

Human complement multiplex kit, Luminex® human complement immunoassay, Millipore human complement panel

登录查看公司和协议定价
所有图片(2)

About This Item

UNSPSC代码:
12161503
eCl@ss:
32161000
NACRES:
NA.47

质量水平

200

种属反应性

human

制造商/商品名称

Milliplex®

assay range

accuracy: 96%
(Mannose-Binding Lectin (MBL))
sensitivity: 0.0051 ng/mL
(Complement C5a)
sensitivity: 0.026 ng/mL
(Adipsin (Complement Factor D))
sensitivity: 0.040 ng/mL
(Mannose-Binding Lectin (MBL))
sensitivity: 0.22 ng/mL
(Complement Factor I)
sensitivity: 0.31 ng/mL
(Complement C2)
sensitivity: 0.36 ng/mL
(Complement C4b)
sensitivity: 1.040 ng/mL
(Complement C5)
standard curve range: 0.069-50 ng/mL
(Adipson/ Complement Factor D)
standard curve range: 0.07-50 ng/mL
(Complement C2)
standard curve range: 0.137-100 ng/mL
(Mannose-Binding Lectin (MBL))
standard curve range: 0.69-500 ng/mL
(Complement Factor I)
standard curve range: 1.37-1,000 ng/mL
(Complement C4b)
standard curve range: 2.74-2,000 ng/mL
(Complement C5)
standard curve range: 4.12-30,000 pg/mL
(Complement C5a)

技术

multiplexing: suitable

检测方法

fluorometric (Luminex xMAP)

运输

2-8°C

相关类别

一般描述

补体系统由大量血浆蛋白组成蛋白，这些蛋白有助于吞噬细胞和抗体清除病原体的能力。有三种不同的同时途径。经典途径由抗原-抗体复合物刺激；替代途径在与致病细胞表面接触时自发激活；甘露糖结合凝集素（MBL）途径识别通常仅存在于致病细胞表面的甘露糖。由于可能对宿主组织造成极大损害，因此必须严格控制补体系统的激活。调节补体控制蛋白（包括CD59，也称为保护素）在血液血浆中的浓度高于补体蛋白本身。补体系统被认为在许多具有免疫成分的疾病中起关键作用，例如哮喘和许多自身免疫性疾病，包括SLE，IBD和多发性硬化。它也越来越多地与神经系统疾病（例如阿尔茨海默氏病）和诸如脊髓损伤之类的疾病相关。

MILLIPLEX®补体面板1珠面板是一种7重试剂盒，用于同时定量血清、血浆或培养上清液样品中以下任何或所有分析物：C2、C4B、C5、C5a、脂联素/补体因子D、MBL和补体因子I。

Luminex® xMAP®平台使用磁珠免疫分析格式，以实现理想的速度和灵敏度，同时定量多种分析物，从而显著提高生产力，同时节省宝贵的样本量。

面板类型：免疫反应

特异性

交叉反应性
抗体与该面板中任何其他分析物之间的交叉反应性都为无法检测或可忽略。

应用

  • 分析物：C2、C4b、C5、C5a、脂联素/因子D、甘露糖结合凝集素（MBL）和因子I
  • 推荐的样品类型：血清，血浆和组织/细胞培养上清液
  • 推荐的样品稀释度：1：200稀释血浆或血清。组织培养上清液可能需要在测定之前用适当的对照培养基稀释
  • 分析运行时间：过夜或2小时初次孵育
  • 研究类别：炎症 & 免疫学
  • 研究子类别：炎症
  • 注释：为避免样品中的补体激活（这将影响结果），应尽快解冻样品，置于冰上并立即进行分析

特点和优势

通过在此面板中选择可用的分析物来设计多重试剂盒。

包装

96孔板

储存及稳定性

试剂盒组分建议的存储温度为2-8°C。

法律信息

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

免责声明

除非我们的产品目录或产品附带的其他公司文档另有说明，否则我们的产品仅供研究使用，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。

警示用语：

Danger

危险分类

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

靶器官

Respiratory Tract

储存分类代码

10 - Combustible liquids

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Ngo Truong Giang et al.
Scientific reports, 10(1), 14923-14923 (2020-09-12)
The complement system may be crucial during dengue virus infection and progression to severe dengue. This study investigates the role of MBL2 genetic variants and levels of MBL in serum and complement proteins in Vietnamese dengue patients. MBL2 genotypes (- 550L/H
Frank Sebastian Fröschen et al.
Diagnostics (Basel, Switzerland), 11(3) (2021-04-04)
The role and diagnostic value of the synovial complement system in patients with low-grade periprosthetic joint infection (PJI) are unclear. We sought to evaluate, for the first time, the usefulness of synovial complement factors in these patients by measuring the
Mikyle David et al.
Archives of gynecology and obstetrics, 304(6), 1467-1473 (2021-04-22)
In preeclampsia, there are excessive complement components expressed due to increased complement activation; therefore, this study investigated the concentration of adipsin and C9 in HIV-associated preeclampsia. The study population (n = 76) was stratified by pregnancy type (normotensive pregnant and preeclampsia) and
Laura McCulloch et al.
F1000Research, 8, 1039-1039 (2019-11-12)
Background: Blockade of the cytokine interleukin-1 (IL-1) with IL-1 receptor antagonist (IL-1Ra) is a candidate treatment for stroke entering phase II/III trials, which acts by inhibiting harmful inflammatory responses.  Infection is a common complication after stroke that significantly worsens outcome
Manjunath Ramanjaneya et al.
Frontiers in endocrinology, 13, 918320-918320 (2022-08-02)
Complement factors mediate the recruitment and activation of immune cells and are associated with metabolic changes during pregnancy. The aim of this study was to determine whether complement factors in the maternal serum and follicular fluid (FF) are associated with
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门